AP
Ajad Patel
About Ajad Patel
Data last updated:
Ajad Patel is a Director at Alismed Pharma Private Limited (since 2023), Designated Partner at 3 Square Infrazone Llp (since 2023) and Designated Partner at 2 Square Infraestate Llp (since 2021). The companies operate in Trading and Real Estate and Construction. The largest current company by reported revenue is Alismed Pharma Private Limited at ₹15.9 Lakh (FY 2025).
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
| Director | 05 Jan 2023 | 2023 | ₹15.9 Lakh (FY 2025) | Active | |
| Designated Partner | 21 Jul 2023 | 2023 | Active | ||
| Designated Partner | 21 Sep 2021 | 2021 | Active |
Board colleagues of Ajad Patel
| Name | DIN | Company | Designation |
|---|---|---|---|
| Sandip Yadav | 09850729 | Alismed Pharma Private Limited | Director |
| Shiv Prakash | 09850728 | Alismed Pharma Private Limited | Director |
| Pooja | 11005967 | 3 Square Infrazone Llp , 2 Square Infraestate Llp | Designated Partner |
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Ajad Patel
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Ajad Patel
Ajad Patel currently holds 3 directorships: Alismed Pharma Private Limited (Director, since 05 Jan 2023, revenue ₹15.9 Lakh (FY 2025)); 3 Square Infrazone Llp (Designated Partner, since 21 Jul 2023); 2 Square Infraestate Llp (Designated Partner, since 21 Sep 2021).
Ajad Patel was first appointed on 21 Sep 2021 as Designated Partner at 2 Square Infraestate Llp. The most recent appointment on record is 21 Jul 2023 at 3 Square Infrazone Llp.
The current boards of Ajad Patel's companies include Sandip Yadav (Alismed Pharma Private Limited), Shiv Prakash (Alismed Pharma Private Limited), Pooja (3 Square Infrazone Llp).